CAS 1322625-54-6

Lopinavir-d8

Produit contrôlé

CAS : 1322625-54-6

Applications A labelled selective HIV protease inhibitor. An analogue of Ritonavir. Antiviral. It is a COVID19-related research product.
References Sham, H.L., et al.: Antimicrob. Ag. Chemother., 42, 3218 (1998), Kumar, G.N., et al.: Drug Metab. Dispos., 27, 86 (1999), Murphy, R.L., et al.: Antiviral Ther., 4, Suppl. 3, 85 (1999)

Formule : C₃₇D₈H₄₀N₄O₅

Couleur et forme : Light Yellow

Masse moléculaire : 636.85

Ref: TR-L469482

Lopinavir-d8

CAS : 1322625-54-6

Lopinavir is an antiviral drug used for the treatment of HIV infection. Lopinavir-d8 is a prodrug that is converted to lopinavir in the body. The conversion rate of lopinavir-d8 to lopinavir in plasma was found to be dependent on a number of factors, such as the type of sample (plasma vs. serum), age, and gender. Lopinavir has been shown to inhibit viral replication by binding to reverse transcriptase and blocking its activity. It also inhibits protease, which prevents the cleavage of polyproteins into functional proteins necessary for viral replication. Lopinavir-d8 has been shown to be effective in treating HIV infection in infants and children.

Formule : C₃₇H₄₈N₄O₅

Degré de pureté : Min. 95%

Masse moléculaire : 636.8 g/mol

Ref: 3D-XCC62554